Unum Group’s (UNM) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their neutral rating on shares of Unum Group (NYSE:UNM) in a report released on Tuesday, MarketBeat Ratings reports. JPMorgan Chase & Co. currently has a $79.00 price target on the financial services provider’s stock, up from their prior price target of $74.00.

Several other equities research analysts have also recently weighed in on UNM. Wells Fargo & Company increased their target price on Unum Group from $69.00 to $71.00 and gave the company an “overweight” rating in a report on Thursday, October 10th. Evercore ISI raised Unum Group from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $67.00 to $84.00 in a research note on Thursday, November 14th. Piper Sandler lifted their target price on shares of Unum Group from $74.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Barclays increased their price target on shares of Unum Group from $76.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Truist Financial boosted their price objective on shares of Unum Group from $70.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $74.55.

Unum Group Stock Down 0.6 %

Shares of UNM opened at $72.96 on Tuesday. The firm has a market cap of $13.32 billion, a P/E ratio of 7.90, a P/E/G ratio of 1.06 and a beta of 0.81. Unum Group has a 1 year low of $44.83 and a 1 year high of $77.63. The stock has a 50 day simple moving average of $72.68 and a two-hundred day simple moving average of $61.80. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.28 and a quick ratio of 0.28.

Unum Group (NYSE:UNM) last announced its quarterly earnings data on Tuesday, October 29th. The financial services provider reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.10 by $0.03. The company had revenue of $3.22 billion during the quarter, compared to analysts’ expectations of $3.26 billion. Unum Group had a net margin of 13.76% and a return on equity of 15.21%. The firm’s revenue was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.94 EPS. On average, analysts forecast that Unum Group will post 8.54 earnings per share for the current fiscal year.

Unum Group Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Friday, January 24th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 2.30%. Unum Group’s dividend payout ratio (DPR) is presently 18.18%.

Insider Activity at Unum Group

In related news, EVP Christopher W. Pyne sold 3,250 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $70.02, for a total value of $227,565.00. Following the transaction, the executive vice president now directly owns 50,762 shares of the company’s stock, valued at approximately $3,554,355.24. This represents a 6.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Walter Lynn Rice, Jr. sold 1,500 shares of Unum Group stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $69.56, for a total value of $104,340.00. Following the completion of the sale, the chief accounting officer now owns 8,361 shares of the company’s stock, valued at $581,591.16. The trade was a 15.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 107,914 shares of company stock worth $7,998,745 over the last ninety days. 0.93% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Natixis Advisors LLC raised its holdings in Unum Group by 3.3% in the 2nd quarter. Natixis Advisors LLC now owns 27,296 shares of the financial services provider’s stock worth $1,395,000 after purchasing an additional 873 shares during the period. Private Advisor Group LLC lifted its position in shares of Unum Group by 1.5% during the 2nd quarter. Private Advisor Group LLC now owns 29,481 shares of the financial services provider’s stock valued at $1,507,000 after buying an additional 437 shares in the last quarter. Savant Capital LLC lifted its position in shares of Unum Group by 1.6% during the 2nd quarter. Savant Capital LLC now owns 41,714 shares of the financial services provider’s stock valued at $2,132,000 after buying an additional 675 shares in the last quarter. Caprock Group LLC increased its holdings in Unum Group by 79.7% in the 2nd quarter. Caprock Group LLC now owns 12,087 shares of the financial services provider’s stock worth $618,000 after acquiring an additional 5,362 shares in the last quarter. Finally, Choreo LLC bought a new stake in Unum Group during the 2nd quarter worth approximately $346,000. Institutional investors own 86.57% of the company’s stock.

Unum Group Company Profile

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.